Showing results (11-20 of 20) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Molecular and Cellular Biology|October 4, 2006
TReP-132 is a novel progesterone receptor coactivator required for the inhibition of breast cancer cell growth and enhancement of differentiation by progesteroneFlorence Gizard, Romain Robillard, Barbara Gross, et al.Journal of Biomolecular Screening|July 31, 2013
The identification of naturally occurring neoruscogenin as a bioavailable, potent, and high-affinity agonist of the nuclear receptor RORα (NR1F1)Stéphane Helleboid, Christian Haug, Kai Lamottke, et al.Journal of Lipid Research|September 3, 2004
Farnesoid X receptor represses hepatic lipase gene expressionAudrey Sirvent, Adrie J M Verhoeven, Hans Jansen, et al.Molecular Neurobiology|May 20, 2014
Pan-PPAR modulation effectively protects APP/PS1 mice from amyloid deposition and cognitive deficitsMarkus P Kummer, Rafael Schwarzenberger, Sakina Sayah-Jeanne, et al.The Journal of Clinical Investigation|April 3, 2002
Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response elementThierry Claudel, Ekkehard Sturm, Hélène Duez, et al.Arteriosclerosis, Thrombosis, and Vascular Biology|March 26, 2005
Transcriptional regulation of apolipoprotein A5 gene expression by the nuclear receptor RORalphaAnnelise Genoux, Hélène Dehondt, Audrey Helleboid-Chapman, et al.Journal of Hepatology|May 24, 2023
NIS2+™, an optimisation of the blood-based biomarker NIS4® technology for the detection of at-risk NASH: A prospective derivation and validation studyStephen A Harrison, Vlad Ratziu, Jeremy Magnanensi, et al.Hepatology (Baltimore, Md.)|May 25, 2013
Hepatoprotective effects of the dual peroxisome proliferator-activated receptor alpha/delta agonist, GFT505, in rodent models of nonalcoholic fatty liver disease/nonalcoholic steatohepatitisBart Staels, Anne Rubenstrunk, Benoit Noel, et al.JHEP Reports : Innovation in Hepatology|March 11, 2024
Impact of age on NIS2+™ and other non-invasive blood tests for the evaluation of liver disease and detection of at-risk MASHQuentin M Anstee, Jeremy Magnanensi, Yacine Hajji, et al.The Lancet. Gastroenterology & Hepatology|August 9, 2020
A blood-based biomarker panel (NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: a prospective derivation and global validation studyStephen A Harrison, Vlad Ratziu, Jérôme Boursier, et al.Pageof 2